

Rett Syndrome Research Trust, Inc.

Financial Statements

December 31, 2021



Rett Syndrome Research Trust, Inc.
December 31, 2021

Table of Contents

	<u>Page</u>
Report of Independent Auditor	1
<u>Financial Statements:</u>	
Statements of Financial Position	3
Statements of Activities	4
Statements of Cash Flows	5
Statements of Functional Expenses	6
Notes to Financial Statements	8
<u>Supplemental Statements:</u>	
Functional Expense Allocation and Research Funded Expense Graphs	15
Research Awards and Grants Commitments and Payments Schedule	16

REPORT OF INDEPENDENT AUDITOR

To the Board of Trustees
Rett Syndrome Research Trust, Inc.

Opinion

We have audited the accompanying financial statements of Rett Syndrome Research Trust, Inc. (a nonprofit organization), which comprise the statements of financial position as of December 31, 2021 and 2020, and the related statements of activities, cash flows and functional expenses for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Rett Syndrome Research Trust, Inc. as of December 31, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Rett Syndrome Research Trust, Inc. and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Rett Syndrome Research Trust, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial

likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Rett Syndrome Research Trust, Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Rett Syndrome Research Trust, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The Supplemental Statements of Functional Expense Allocation and Research Funded Expense Graphs, and the Research Awards and Grant Commitments and Payments Schedule is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Knight Rolleri Sheppard CPAS, LLP

Knight Rolleri Sheppard CPAS, LLP
Fairfield, Connecticut
May 12, 2022

Rett Syndrome Research Trust, Inc.
Statements of Financial Position
December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
<u>ASSETS</u>		
Current assets		
Cash and cash equivalents	\$ 11,909,266	\$ 9,864,917
Promises to give	1,159,853	1,309,317
Investments	1,058	-
Total current assets	13,070,177	11,174,234
Other assets		
Promises to give	511,840	803,041
Total other assets	511,840	803,041
Total assets	\$ 13,582,017	\$ 11,977,275
<u>LIABILITIES AND NET ASSETS</u>		
Current liabilities		
Accounts payable	\$ -	\$ 3,008
Grants payable	4,652,824	5,971,624
Accrued expenses	11,499	9,999
Total current liabilities	4,664,323	5,984,631
Other liabilities		
Grants payable	1,023,222	1,483,861
Total other liabilities	5,687,545	7,468,492
Net assets without donor restrictions		
Undesignated	7,894,472	4,508,783
Total net assets	7,894,472	4,508,783
Total liabilities and net assets	\$ 13,582,017	\$ 11,977,275

See report of independent auditor and notes to financial statements.

Rett Syndrome Research Trust, Inc.
Statements of Activities
For the Years Ended December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Public support and revenues		
Contributions	\$ 7,181,367	\$ 7,223,717
The Eva Fini Fund	97,435	-
The MECP2 Duplication Syndrome Fund	547,223	440,894
Licensing	78,903	22,888
Biorepository	36,170	-
Donated services and rent	8,000	8,000
Interest income	29,868	62,327
Realized losses from sales of donated securities	(1,550)	(82)
PPP loan forgiveness	155,395	155,300
Total public support and revenues	<u>8,132,811</u>	<u>7,913,044</u>
Expenses		
Program services	4,166,586	2,507,176
Supporting services:		
Management and general	131,269	259,706
Fundraising	449,267	307,838
Total expenses	<u>4,747,122</u>	<u>3,074,720</u>
Grants terminated and modified	-	6,119,384
Increase in net assets from operations	<u>3,385,689</u>	<u>10,957,708</u>
Net assets (deficit) - beginning of year	<u>4,508,783</u>	<u>(6,448,925)</u>
Net assets - end of year	<u><u>\$ 7,894,472</u></u>	<u><u>\$ 4,508,783</u></u>

See report of independent auditor and notes to financial statements.

Rett Syndrome Research Trust, Inc.
Statements of Cash Flows
For the Years Ended December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Cash flows from (used in) operating activities		
Increase in net assets	\$ 3,385,689	\$ 10,957,708
Adjustments to reconcile decrease in net assets to cash from (used in) operating activities		
Depreciation	-	1,060
PPP loan forgiveness	(155,395)	(155,300)
(Increase) decrease in promises to give	440,665	(545,211)
(Increase) decrease in investments from donor donations held for sale	(1,058)	1,100
Decrease in accounts payable	(3,008)	(3,219)
Increase (decrease) in accrued expenses	1,500	(15,682)
Decrease in grants payable	(1,779,439)	(8,762,847)
Net cash provided from operating activities	<u>1,888,954</u>	<u>1,477,609</u>
Cash flows from financing activities		
Proceeds from PPP loan	<u>155,395</u>	<u>155,300</u>
Net cash provided from investing activities	<u>155,395</u>	<u>155,300</u>
Increase in cash	<u>2,044,349</u>	<u>1,632,909</u>
Cash and cash equivalents - beginning of year	<u>9,864,917</u>	<u>8,232,008</u>
Cash and cash equivalents - end of year	<u><u>\$11,909,266</u></u>	<u><u>\$ 9,864,917</u></u>

See report of independent auditor and notes to financial statements.

Rett Syndrome Research Trust, Inc.
Statement of Functional Expenses
For the Year Ended December 31, 2021

	<u>Program</u>	<u>Supporting Services</u>		<u>Total Expenses</u>
		<u>Management and General</u>	<u>Fundraising</u>	
Awards and grants	\$ 3,172,189	\$ -	\$ -	\$ 3,172,189
Bank and credit card fees	2,543	275	772	3,590
Bookkeeping	-	815	-	815
Employee benefits	31,875	3,450	9,671	44,996
Fundraising	-	-	163,636	163,636
Insurance	1,972	1,971	1,971	5,914
Miscellaneous	59,038	4,037	11,366	74,441
Office and supplies	2,567	9,246	779	12,592
Payroll taxes	45,758	4,953	13,883	64,594
Postage and shipping	2,695	292	818	3,805
Printing and publication	2,206	26	129	2,361
Professional fees (*)	132,818	29,707	31,769	194,294
Rent (**)	2,125	230	645	3,000
Salaries	702,222	76,009	213,056	991,287
Scientific meetings	250	-	-	250
Telephone	2,175	235	660	3,070
Travel - scientific meetings	4,244	-	-	4,244
Website and hosting	1,909	23	112	2,044
	<u>\$ 4,166,586</u>	<u>\$ 131,269</u>	<u>\$ 449,267</u>	<u>\$ 4,747,122</u>

(*) Includes \$5,000 of donated services.

(**) Includes \$3,000 donated rent.

See report of independent auditor and notes to financial statements.

Rett Syndrome Research Trust, Inc.
Statement of Functional Expenses
For the Year Ended December 31, 2020

	<u>Program</u>	<u>Supporting Services</u>		<u>Total Expenses</u>
		<u>Management and General</u>	<u>Fundraising</u>	
Awards and grants	\$ 1,518,003	\$ -	\$ -	\$ 1,518,003
Bank and credit card fees	2,872	491	812	4,175
Bookkeeping	-	1,078	-	1,078
Depreciation	971	61	28	1,060
Employee benefits	30,117	5,154	8,515	43,786
Fundraising	-	-	45,276	45,276
Insurance	1,910	1,908	1,908	5,726
Miscellaneous	27,501	2,409	3,818	33,728
Office and supplies	35	7,771	10	7,816
Payroll taxes	53,083	9,085	15,009	77,177
Postage and shipping	3,452	591	976	5,019
Printing and publication	4,323	273	124	4,720
Professional fees (*)	42,695	90,727	-	133,422
Rent (**)	2,741	469	775	3,985
Salaries	812,469	139,050	229,716	1,181,235
Scientific meetings	3,499	-	-	3,499
Telephone	2,834	485	801	4,120
Travel - scientific meetings (refund)	(1,758)	-	-	(1,758)
Website and hosting	2,429	154	70	2,653
	<u>\$ 2,507,176</u>	<u>\$ 259,706</u>	<u>\$ 307,838</u>	<u>\$ 3,074,720</u>

(*) Includes \$5,000 of donated services.

(**) Includes \$3,000 donated rent.

See report of independent auditor and notes to financial statements.

Rett Syndrome Research Trust, Inc.
Notes to Financial Statements
December 31, 2021
(See Report of Independent Auditor)

NOTE 1 – ORGANIZATION

Rett Syndrome Research Trust, Inc. (the “Organization” and “RSRT”) is a not-for-profit organization formed under Internal Revenue Code 501(c)(3). The Organization is focused on the development of treatments and cures for Rett Syndrome and related *MECP2* disorders. The Organization funds research projects and organizes and sponsors scientific workshops. Equally important, RSRT brings to the scientific community a deep knowledge of the disease and access to intellectual capital. It provides a comprehensive view of the field and a focus on translational efforts.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting and Presentation

The financial statements of the Organization have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP). Accordingly, the accounts of the Organization are reported by net asset category. Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions – Net assets available for use in general operations and not subject to donor (or certain grantor) restrictions.

Net Assets With Donor Restrictions – Net assets subject to donor (or certain grantor) imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. The Organization reports contributions restricted by donors as increase in net assets without donor restriction if the restrictions expire (that is, when stipulated time restriction ends or purpose restriction is accomplished) in the reporting period in which the revenue is recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions, depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net asset without donor restrictions and reported in the statements of activities as net assets released from restrictions.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. These assumptions can include depreciable lives of long-lived assets, allocation of functional expenses and discount factors used to record long-term promises to give and long-term grants payable to name a few. Actual results could differ from those estimates.

Cash Equivalents

For purposes of the statement of cash flows, the Organization considers all highly liquid debt instruments purchased with maturity of three months or less to be cash equivalents. The Organization maintains its cash accounts at various financial institutions across the State of Connecticut. Accounts are guaranteed by the FDIC up to \$250,000 per financial institution.

Rett Syndrome Research Trust, Inc.
Notes to Financial Statements
December 31, 2021
(See Report of Independent Auditor)

The balance in excess of FDIC limitations is \$12,041,643 at December 31, 2021. The Organization has not experienced any losses in such accounts and believes it is not exposed to any significant risk in maintaining accounts with the financial institutions.

Promise to Give and Allowance for Uncollectable Accounts

Promises to give are stated net of an allowance for doubtful accounts and valuation discount. The Organization estimates the allowance based on its historical experience of the relationship between actual bad debts and promises to give. As of December 31, 2021, management believes that all promises are fully collectable as there has been no history of any bad debts.

Revenue and Revenue Recognition

In May 2014, the FASB issued FASB ASU 2014-09: *Revenue from Contracts with Customers*, which clarifies the principles for recognizing revenue. This guidance includes the required steps to achieve the core principle that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Organization adopted this guidance as of January 1, 2020. The adoption of this standard had an immaterial effect on the financial statements.

The Organization recognize contributions when cash, securities or other assets, an unconditional promise to give, or notification of a beneficial interest is received. Conditional promises to give, that is, those with a measurable performance or other barrier, and a right of return, are not recognized until the conditions on which they depend have been substantially met.

Contributions

In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-08: *Not-For-Profit Entities: Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made*, which clarifies and improves the scope and the accounting guidance for contributions received and contributions made. The amendments assist entities in (1) evaluating whether transactions should be accounted for as contributions (nonreciprocal transactions) within the scope of Accounting Standards Codification (“ASC”) Topic 958, Not-for-Profit Entities, or as exchange (reciprocal) transactions subject to other guidance and determining whether a contribution is conditional. The Organization adopted this guidance as of January 1, 2020, prospectively. Under this approach, prior financial statements are not restated, and a cumulative effect adjustment is not recognized upon adoption. The impact of the adoption had no impact on the financial statements.

Donated Facilities and Services

The Organization records the value of donated facilities as revenue with an equivalent amount recorded as expense. The value of this donation is \$3,000 for the years ended December 31, 2021 and 2020. Contributed services that create or enhance non-financial assets and require a specialized skill are reported as contributions at their fair value with a corresponding amount recorded as an expense. The value of contributed services reflected as professional services is \$5,000 each for the years ended December 31, 2021 and 2020, respectively.

Property and Equipment

Property and equipment is recorded at cost and is being depreciated over three years.

Rett Syndrome Research Trust, Inc.
Notes to Financial Statements
December 31, 2021
(See Report of Independent Auditor)

Functional Expenses

The Organization allocates its expenses on a functional basis among its program and support services. Expenses that can be specifically identified with a program or support service are allocated directly according to their natural classifications. Other expenses that are common to several functions are allocated based upon estimates made by management.

NOTE 3 – LIQUIDITY AND AVAILABILITY

Financial assets available for general expenditure, that is, without donor and other restrictions limiting their use, within one year of the statement of financial position date, comprise the following:

Cash and cash equivalents	\$ 11,909,266
Promises to give	1,159,853
	<u>\$ 13,069,119</u>

The Organization has committed significant resources to research grants within one year of the statement of financial position date. Meeting those commitments require collection of promises to give due within one year along with ongoing fundraising efforts for additional funds.

As part of the organization’s liquidity management plan, RSRT invest cash in excess of daily requirements in short-term investments and money market funds.

NOTE 4 – FAIR VALUE MEASUREMENT

The Organization follows guidance as set forth in the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements for fair value measurements. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of fair value hierarchy under FASB ASC 820 are described as follows:

Fair value measurement – the Organization determines fair value based on assumptions that market participants would use pricing an asset or liability in the principal or most advantageous market. The Company follows the fair value hierarchy when distinguishing assumptions in fair value measurement as outlined in the FASB “Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures”.

- Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.
- Level 2 – Observable inputs other than quoted prices included in level 1 that are observable for the asset or liability, either directly or indirectly and include;
 - Quoted prices for similar assets or liabilities in active markets.

Rett Syndrome Research Trust, Inc.
Notes to Financial Statements
December 31, 2021
(See Report of Independent Auditor)

- Quoted prices for identical or similar assets or liabilities in inactive markets.
- Market prices for similar instruments.
- Inputs other than quoted prices that are observable for the asset or liability.
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

- Level 3 – Inputs to the valuation methodology are unobservable and significantly to the fair value measurement.

The availability of valuation techniques and observable inputs can vary from investment to investment and are impacted by factors such as investment type, whether the investment is new and not established in a marketplace, the liquidity of markets, and other transaction characteristics. To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, determining fair value requires more judgment. Because of the inherent uncertainty of valuation, estimated values may be materially higher or lower than the values that would have been used had a ready market for the investment existed. Therefore, the degree of judgment used by the Company in determining fair value is greatest for investments categorized in level 3. Inputs used to measure fair value might be categorized within different levels of fair value hierarchy and are categorized based upon the lowest level of input that is significant to the fair value measurement.

The following is a description of the valuation methodologies used for assets measured at fair value:

Promises to Give – promises to give are values based on discounted cash flows reduced by an allowance of collectability.

There have been no changes in methodologies used at December 31, 2021.

Rett Syndrome Research Trust, Inc.
Notes to Financial Statements
December 31, 2021

The following table summarizes the changes in the fair value of the Organization's Level 3 assets for the year ended December 31, 2021 and 2020:

	Promises to Give	
	<u>2021</u>	<u>2020</u>
Balance - beginning of year	\$ 2,132,077	\$ 1,569,232
New promises to give	868,865	1,357,668
Collections	<u>(1,312,998)</u>	<u>(794,823)</u>
Balance - end of year	<u>\$ 1,687,944</u>	<u>\$ 2,132,077</u>

NOTE 5 – INCOME TAXES

The Organization has been granted tax-exempt status by the Internal Revenue Service under Internal Revenue Code Section 501(c)(3). Accordingly, no provision for federal or state income taxes has been recorded in the accompanying financial statements. Management of the Organization does not believe it has any uncertain tax positions. The Organization's tax returns remain open to examination by regulatory authorities from December 31, 2019.

NOTE 6 – PROMISES TO GIVE

At December 31, 2021 and 2020, contributors to the Organization have unconditionally promised to give \$1,687,944 and \$2,132,077, respectively. Long-term promises have been discounted at 2% per annum which the Organization believes to be its risk-free rate of return. The promised contributions are due as follows:

	<u>2021</u>	<u>2020</u>
Within one year	\$ 1,159,853	\$ 1,309,317
One to five years	528,091	822,760
More than five years	-	-
Subtotal	<u>1,687,944</u>	<u>2,132,077</u>
Less: present value component	(16,251)	(19,719)
Less: allowance for doubtful accounts	-	-
Promises to give, net	<u>\$ 1,671,693</u>	<u>\$ 2,112,358</u>

Management has evaluated all promises to give and believes that a reserve for uncollectable accounts is not warranted as there has never been any history of write-offs.

All promises to give have valued using level 3 criteria as described in Note 4 to the financial statements.

NOTE 7 – GRANTS PAYABLE

The Organization has committed to unconditional promises to give of \$5,698,829 and \$7,486,737 as of December 31, 2021 and 2020, respectively to various research organizations over the next several years. Long-term commitments have been discounted at 2% per annum which the Organization believes to be its risk-free rate of return. The timing of future grants payable is as follows:

Rett Syndrome Research Trust, Inc.
Notes to Financial Statements
December 31, 2021
(See Report of Independent Auditor)

	<u>2021</u>	<u>2020</u>
Within one year	\$ 4,652,824	\$ 5,971,624
One to five years	1,046,005	1,515,113
More than five years	-	-
Subtotal	<u>5,698,829</u>	<u>7,486,737</u>
Less: present value component	<u>(22,783)</u>	<u>(31,252)</u>
Grants payable, net	<u>\$ 5,676,046</u>	<u>\$ 7,455,485</u>

Future funding of committed grants is predicated upon anticipated fundraising activities.

NOTE 8 – CONCENTRATIONS

The Organization has several donors that have provided at least 10% of aggregate contributions for the year ended December 31, 2021.

NOTE 9 – PAYCHECK PROTECTION LOAN

The Organization applied for and received a loan for \$155,395 under the “Paycheck Protection Program”. Under this program loans used for certain expenses of the organization would qualify for loan forgiveness. The Organization expended all funds on qualifying expenses and applied for and received loan forgiveness for the full amount of the loan. The forgiveness is included in the statement of activities.

NOTE 10 - RISKS AND UNCERTAINTIES

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on the Organization’s financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation on its financial condition, liquidity, operations, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Organization is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for the year ended December 31, 2022.



Management believes it is well-positioned with enough liquid resources from current reserves to maintain operations through the pandemic.

Rett Syndrome Research Trust, Inc.
Notes to Financial Statements
December 31, 2021
(See Report of Independent Auditor)

NOTE 11 – SUBSEQUENT EVENTS

In accordance with FASB Accounting Standards Codification 855, Subsequent Events, the Organization has evaluated subsequent events to the Statement of Financial Position date of December 31, 2021 through May 12, 2022, which is the date the financial statements were available to be issued. Management has determined that there are no events occurring subsequent to the end of the year that require any disclosures or adjustments.

Rett Syndrome Research Trust, Inc.
Supplemental Statement - Functional Expense Allocation and
Research Funded Expense Graphs
For the Year Ended December 31, 2021



See report of independent auditor.

Rett Syndrome Research Trust, Inc.
Supplemental Statement - Research Awards and Grant Commitments and Payments Schedule
For the Year Ended December 31, 2021

	<u>Commitment at December 31, 2020</u>	<u>Additional Commitments</u>	<u>Payments Against Commitments</u>	<u>Commitment at December 31, 2021</u>
Fred Hutchinson Cancer Research Antonio Bedalov	\$ -	\$ 550,239	\$ (134,895)	\$ 415,344
Gene Therapy Consortium University of Edinburgh University of Pennsylvania	525,138	623	(525,761)	-
Children's Hospital at Montefiore	-	25,000	(25,000)	-
Ketamine Trial	567,215	-	(53,780)	513,435
Queen Mary University of London Andrea Cerase	85,000	-	(85,000)	-
OHSU John Sinnamon	143,750	-	(115,000)	28,750
University of California Davis Peter Beal	262,813	-	(174,200)	88,613
Kyle Fink	-	540,680	(131,292)	409,388
Joseph Anderson	-	186,254	-	186,254
Beam Therapeutics	639,300	-	(639,300)	-
MIT Guoping Feng	918,502	-	(612,334)	306,168
Children's Hospital of Philadelphia Joni Saby and Eric Marsh	-	125,179	-	125,179
Emory University Victor Faundez	-	584,304	(68,935)	515,369
University of Massachusetts Medical School Jonathan Watts	1,248,937	-	(641,740)	607,197
Clinical Trial Consortium	38,381	67,821	(106,202)	-
Rett Syndrome Global Registry	651,000	-	(180,263)	470,737
OMBD Consortium	690,650	-	(2,602)	688,048
ORCA	72,225	15,294	(87,519)	-
California Institute of Technology Michael Elowitz	53,898	-	(53,898)	-
University of Edinburgh Stuart Cobb/Chris Sibley	87,701	-	(87,701)	-
Stuart Cobb/Faundez	-	47,013	(47,013)	-
Harvard Stem Cell Institute	-	36,343	(36,343)	-
Emerald	103,165	-	(21,444)	81,721
Jackson Laboratories	189,565	-	(88,296)	101,269
Coriell Institute for Medical Research	97,224	53,612	(150,836)	-

See report of independent auditor.

Rett Syndrome Research Trust, Inc.
Supplemental Statement - Research Awards and Grant Commitments and Payments Schedule
For the Year Ended December 31, 2021

	<u>Commitment at December 31, 2020</u>	<u>Additional Commitments</u>	<u>Payments Against Commitments</u>	<u>Commitment at December 31, 2021</u>
Citizen	30,000	444,000	(178,000)	296,000
MECP2 Duplication Syndrome				
Baylor College of Medicine Screen - Huda Zoghbi	381,745	-	(189,576)	192,169
University of Massachusetts Medical School Annastasia Khvorova	273,028	-	(218,311)	54,717
Texas Children's Hospital Dazut Pehlivan	-	125,000	-	125,000
Jackson Labs (Khvorova)	-	362,930	(106,959)	255,971
Hospital for Sick Kids Ronald Cohn	427,500	-	(190,000)	237,500
	<u>\$ 7,486,737</u>	<u>\$ 3,164,292</u>	<u>\$ (4,952,200)</u>	<u>\$ 5,698,829</u>

See report of independent auditor.